Reuters
02 Jun 2026, 21:43 UTC · 18w ago
Verdict
Headline leans bearish. We score LLY −0.60 across one claim.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.60strongly bearish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Cigna will stop covering GLP-1 weight-loss drugs, including Wegovy and Zepbound, in its employee health plan effective July 1.
More negative than 95% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More negative than 75% of ticker scores this week
Scored by the NIS engine · methodology.
More negative than 75% of ticker scores this week
Its weight-loss drug Zepbound will no longer be covered by Cigna's employee plan.
More negative than 75% of ticker scores this week
One of its key weight-loss drugs, Wegovy, will no longer be covered by Cigna's employee plan.
More positive than 57% of ticker scores this week
Cigna is reducing costs by stopping coverage of expensive GLP-1 drugs for its employees.
More positive than 34% of relationship scores this week
[a_to_b] Cigna's employee health plan has previously covered Eli Lilly's drug Zepbound.
More positive than 34% of relationship scores this week
[a_to_b] Cigna's employee health plan has previously covered Novo Nordisk's drug Wegovy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Schaeffers Research
22h ago
+9.9%
Price is moving against the score
$1169.93 vs $1064.15 close before publication (Jun 2) · not market-adjusted
LLY chart →
